Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

• Published in: Nature medicine Vol. 27; no. 2; pp. 256 - 263
• Main Authors: Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L. G., Shannon, K., Haanen, J. B. A. G., Stretch, J., Ch’ng, S., Nieweg, O. E., Mallo, H. A., Adriaansz, S., Kerkhoven, R. M., Cornelissen, S., Broeks, A., Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Peeper, D. S., Spillane, A. J., van Akkooi, A. C. J., Scolyer, R. A., Schumacher, T. N. M., Menzies, A. M., Long, G. V., Blank, C. U.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.02.2021; Nature Publishing Group
• Subjects: 631/250/251; 631/67/1813/1634; 692/308/2779/109; 692/53/2423; Adult; Antibodies; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Apoptosis; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - genetics; B7-H1 Antigen - immunology; Biological markers; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - immunology; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cell death; Clinical trials; CTLA-4 Antigen - antagonists & inhibitors; CTLA-4 Antigen - genetics; CTLA-4 Antigen - immunology; Disease-Free Survival; Drug therapy; Female; Gene expression; Health aspects; Humans; Immunotherapy; Immunotherapy - adverse effects; Infectious Diseases; Interferon; Interferon-gamma - genetics; Ipilimumab; Ipilimumab - administration & dosage; Ipilimumab - adverse effects; Letter; Male; Medicin och hälsovetenskap; Melanoma; Melanoma - drug therapy; Melanoma - immunology; Melanoma - pathology; Metabolic Diseases; Middle Aged; Molecular Medicine; Monoclonal antibodies; Mutation - genetics; Neoadjuvant Therapy - adverse effects; Neoplasm Staging; Neurosciences; Nivolumab - administration & dosage; Nivolumab - adverse effects; Patient outcomes; Patients; PD-1 protein; Recurrence; Survival; Testing; γ-Interferon; Netherlands
• ISSN: 1078-8956; 1546-170X; 1546-170X
• DOI: 10.1038/s41591-020-01211-7

Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo ( NCT02977052 ) studies 1 , 2 . While the results are promising, data on the durability of these pathologic responses and baseline biomarkers for response and survival were lacking. After a median follow-up of 4 years, none of the patients with a pathologic response ( n  = 7/9 patients) in the OpACIN study had relapsed. In OpACIN-neo ( n  = 86), the 2-year estimated relapse-free survival was 84% for all patients, 97% for patients achieving a pathologic response and 36% for nonresponders ( P  < 0.001). High tumor mutational burden (TMB) and high interferon-gamma-related gene expression signature score (IFN-γ score) were associated with pathologic response and low risk of relapse; pRR was 100% in patients with high IFN-γ score/high TMB; patients with high IFN-γ score/low TMB or low IFN-γ score/high TMB had pRRs of 91% and 88%; while patients with low IFN-γ score/low TMB had a pRR of only 39%. These data demonstrate long-term benefit in patients with a pathologic response and show the predictive potential of TMB and IFN-γ score. Our findings provide a strong rationale for a randomized phase 3 study comparing neoadjuvant ipilimumab plus nivolumab versus standard adjuvant therapy with antibodies against the programmed cell death protein-1 (anti-PD-1) in macroscopic stage III melanoma. Long-term outcomes and biomarker analyses of two neoadjuvant immunotherapy clinical trials in melanoma patients support the clinical benefit of this treatment approach and uncover prognostic correlates of response.